Jump to content
Content on WikiMesothelioma is reviewed by three named attorneys at Danziger & De Llano LLP prior to publication. See our editorial standards.

FDA and EPA Regulations on Talc Asbestos Testing

From WikiMesothelioma — Mesothelioma Knowledge Base
Revision as of 11:17, 1 June 2026 by MesotheliomaSupport (talk | contribs) (Publish NET-NEW Legal wiki: FDA/EPA talc asbestos testing regulations. CLEO PASS #12413, commit b947eab, refs 12/12.)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)


Talc Asbestos Testing Regulation
At a Glance
Federal testing rule Proposed Dec 27, 2024; withdrawn Nov 28, 2025
Governing statute MoCRA of 2022 (mandate still in force)
Mandatory U.S. testing? None currently required
FDA 2019 survey 9 of 52 products positive (enriched sample)
EPA action Chrysotile Risk Management Rule (March 2024)
EU status CMR 1B classification; cosmetics ban expected ~2027
Docket FDA-2023-N-4225

Executive Summary

FDA and EPA regulation of asbestos testing in talc is, as of 2026, defined more by what the United States does not require than by what it does. On November 28, 2025, the U.S. Food and Drug Administration formally withdrew its proposed rule that would have required standardized asbestos testing of talc-containing cosmetics, leaving no mandatory federal testing standard in place even though the agency's authorizing statute still directs it to create one.[1][2] Asbestos contamination of cosmetic talc is a recognized exposure pathway, because talc and asbestos are naturally occurring minerals that form in close proximity in the earth and can be co-mined.[3] The central regulatory fact in 2026 is a gap: the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) directed the FDA to establish standardized testing methods for detecting asbestos in talc-containing cosmetics, the FDA proposed such a rule on December 27, 2024 (89 FR 105490), and the agency then withdrew that proposed rule on November 28, 2025 under docket FDA-2023-N-4225.[1][3] The Federal Register notice states the withdrawal was made in response to comments received during the comment period that warrant further consideration and assessment before final regulations are issued; it gives no timeline for a replacement.[1]

The withdrawal does not erase the statutory obligation. MoCRA's directive to establish testing methods remains in force, so the FDA still carries an unmet legal mandate while no enforceable testing requirement exists for manufacturers.[4][2] In the regulatory vacuum, asbestos testing of cosmetic talc in the United States is voluntary and company-led.

The agency's own data shows why testing matters. In its 2019 sampling assignment the FDA found asbestos in 9 of 52 talc-containing cosmetic products tested — but the FDA itself cautions that this rate should not be read as a marketplace contamination frequency, because the sample was deliberately weighted toward products with prior contamination concerns.[5][6] The EPA, meanwhile, finalized its Risk Management Rule for Chrysotile Asbestos in March 2024 and separately assessed asbestos-containing talc as a potential exposure source.[7] The European Union has moved in the opposite direction, classifying talc as a carcinogen and preparing a cosmetics ban expected around 2027.[8]

At-a-Glance

Talc asbestos testing regulation at a glance:

  • Proposed Dec 27, 2024, withdrawn Nov 28, 2025 — the FDA's standardized asbestos-testing rule for talc cosmetics published as 89 FR 105490 and was withdrawn under docket FDA-2023-N-4225.[1][3]
  • Withdrawal reason was procedural, not substantive — the Federal Register notice cites comments warranting "further consideration and assessment" before final rules, with no replacement timeline given.[1]
  • MoCRA mandate survives the withdrawal — the Modernization of Cosmetics Regulation Act of 2022 still directs the FDA to establish standardized testing methods.[4]
  • No mandatory U.S. testing exists — in the absence of a final rule, asbestos testing of cosmetic talc is voluntary and company-led.[2]
  • The proposed rule required two methods — Polarized Light Microscopy (PLM) and Transmission Electron Microscopy with Energy Dispersive Spectroscopy and Selected Area Electron Diffraction (TEM/EDS/SAED).[3]
  • FDA 2019 survey: 9 of 52 positive — but the FDA states this is not a marketplace rate because the sample was enriched with previously flagged products.[6]
  • EPA Chrysotile Rule finalized March 2024 — prohibiting ongoing uses of chrysotile, the only form of asbestos still imported and processed in the U.S.[7]
  • EPA assessed asbestos-containing talc — as part of its asbestos risk evaluation, "because talc has been implicated as a potential source of asbestos exposure."[7]
  • IARC classifies talc as probably carcinogenic (Group 2A) — and continues to classify asbestos-containing talc within Group 1, "Asbestos."[9][10]
  • EU cosmetics ban expected ~2027 — following an ECHA Risk Assessment Committee CMR Category 1B classification of talc.[8]

Key Facts

Measure Finding (Source)
Proposed rule published December 27, 2024 — 89 FR 105490 (FDA proposed rule)[3]
Proposed rule withdrawn November 28, 2025 — docket FDA-2023-N-4225 (Federal Register)[1]
Authorizing statute Modernization of Cosmetics Regulation Act of 2022 — mandate to set testing methods (FDA)[4]
Required test methods (proposed) PLM and TEM/EDS/SAED — both required per the proposed rule (FDA)[3]
FDA 2019 survey result 9 of 52 products positive — sample enriched with flagged products; not a marketplace rate (FDA, 2019)[6]
FDA 2023 testing Ongoing official-sample testing program continued (FDA, 2023)[11]
EPA asbestos rule Risk Management Rule for Chrysotile Asbestos — finalized March 2024 (EPA)[7]
IARC classification Talc: Group 2A (probably carcinogenic); asbestos-containing talc remains Group 1 (IARC Vol. 136, 2024)[10]
EU regulatory direction CMR Category 1B classification; cosmetics ban expected ~2027 (ECHA RAC)[8]

What did the FDA's withdrawn talc asbestos testing rule require?

The withdrawn rule was the FDA's first attempt to create a binding, standardized method for detecting asbestos in talc-containing cosmetic products. Published in the Federal Register on December 27, 2024 (89 FR 105490), the proposed rule would have required manufacturers of talc-containing cosmetics to test for asbestos using two complementary analytical methods: Polarized Light Microscopy (PLM) and Transmission Electron Microscopy paired with Energy Dispersive Spectroscopy and Selected Area Electron Diffraction (TEM/EDS/SAED).[3] The two-method approach reflects a long-standing technical debate in asbestos analysis: PLM is the traditional screening method, while TEM can detect the thinner fibers and smaller particles that PLM may miss, making the combination more sensitive than either method alone.

Under the proposed framework, the testing obligation flowed directly from the Modernization of Cosmetics Regulation Act of 2022, which for the first time gave the FDA explicit authority and a specific direction to address asbestos in talc.[4] Talc and asbestos are both naturally occurring silicate minerals that can form side by side in the same geological deposits, which is why the FDA frames contamination as a mining-and-sourcing problem rather than an additive problem: asbestos is not added to cosmetics, but it can travel with talc that is not carefully sourced and tested.[3][12]

Why did the FDA withdraw the rule?

According to the Federal Register withdrawal notice, the FDA withdrew the proposed rule "in response to comments received during the comment period" that, in the agency's assessment, warrant "further consideration and assessment" before it issues final regulations.[1] The notice frames the action as a postponement of finalization pending additional review of public comments — a procedural decision on the record — rather than a repudiation of the underlying concern. Importantly, the Federal Register document gives no timeline for a replacement rule and no description of how a future rule might differ.[1]

That distinction matters. Secondary commentary surrounding the withdrawal attributed it to shifting executive-branch priorities, but the controlling regulatory record — the Federal Register notice itself — rests the decision on the comment process and the need for further assessment.[1] On a regulatory page, the agency's own stated basis is the authoritative one.

Does the FDA still have to act after withdrawing the rule?

Yes. The withdrawal removed a proposed rule, not the statute behind it. The Modernization of Cosmetics Regulation Act of 2022 directs the FDA to establish standardized testing methods for detecting and identifying asbestos in talc-containing cosmetic products, and that statutory mandate remains in force after the withdrawal.[4][2] The practical result is a regulatory gap with two halves: the FDA carries an unfulfilled legal obligation to write a testing standard, while manufacturers face no enforceable federal requirement to test in the meantime. Until a final rule is issued, asbestos testing of cosmetic talc in the United States is voluntary and determined by each company.[2]

What did the FDA's own testing find?

The FDA has run its own talc-testing programs, and the results are part of the public regulatory record. In a year-long sampling assignment whose results were released in 2019 (final report 2020), the agency tested 52 talc-containing cosmetic products and found asbestos in 9 of them, with 43 testing negative.[5][6]

The single most important qualification on that figure comes from the FDA itself: the agency states that the occurrence of positive samples in the 2019 testing "should not be interpreted as reflecting the overall frequency of positive samples in the marketplace," because the products were deliberately selected to include items previously reported by third parties to be contaminated, along with children's products and popular powders.[6] In other words, the sample was intentionally weighted toward higher-risk products, so the 9-of-52 result is a finding about a targeted sample, not a population-wide contamination rate. Any responsible use of the figure must carry that caveat.

The FDA continued official-sample testing in subsequent years, including a 2023 testing round conducted through an outside laboratory, demonstrating that the agency has not abandoned surveillance even without a binding testing rule on the books.[11]

How does the EPA's 2024 asbestos rule address talc?

The Environmental Protection Agency regulates asbestos under the Toxic Substances Control Act (TSCA), on a separate track from the FDA's cosmetics authority. In March 2024 the EPA finalized its Risk Management Rule for Chrysotile Asbestos, which prohibits ongoing uses of chrysotile — described by the EPA as the only known form of asbestos currently imported, processed, and distributed in the United States — across uses such as asbestos diaphragms, sheet gaskets, oilfield brake blocks, and aftermarket automotive friction products.[7]

Talc enters the EPA's analysis directly. The agency states that it "assessed the relevant conditions of use of asbestos-containing talc because talc has been implicated as a potential source of asbestos exposure."[7] In a second part of the asbestos evaluation released in November 2024, the EPA examined legacy uses and disposals of asbestos covering chrysotile plus five additional fiber types — crocidolite, amosite, anthophyllite, tremolite, and actinolite — as well as Libby Amphibole Asbestos, and determined that legacy asbestos uses significantly contribute to the unreasonable risk that asbestos presents.[7] The EPA framework therefore recognizes asbestos-contaminated talc as a genuine exposure pathway, even though cosmetics-specific testing falls to the FDA.

How does U.S. talc regulation compare to the European Union?

The United States and the European Union are moving in opposite directions. The EU's Risk Assessment Committee (RAC), housed within the European Chemicals Agency (ECHA), classified talc as a CMR — carcinogenic, mutagenic, or toxic for reproduction — substance in Category 1B. Under Article 15 of the EU Cosmetics Regulation (Regulation (EC) No 1223/2009), substances classified as CMR Category 1A or 1B are, with narrow exceptions, prohibited in cosmetic products. The practical consequence is that talc is expected to be added to the regulation's list of prohibited substances, with a cosmetics ban anticipated around 2027.[8]

The contrast is sharp: where the EU is preparing to phase talc out of cosmetics on a classification-driven timeline, the United States currently has no mandatory asbestos-testing requirement for cosmetic talc at all. U.S. manufacturers that export to Europe will nonetheless have to meet EU classification and phase-out requirements regardless of the domestic regulatory posture, which means the EU rule may shape the global cosmetics supply chain even inside the United States.[8]

Why does the regulatory gap matter for talc litigation?

The regulatory record has become a recurring feature of talc litigation. Several facts coexist in the public regulatory record: the IARC classifies talc as probably carcinogenic to humans (Group 2A) and continues to place asbestos-containing talc in Group 1 within "Asbestos";[9][10] the FDA's own sampling has documented asbestos in talc products; and MoCRA directs the FDA to set a testing standard that, as of 2026, does not exist because the proposed rule was withdrawn.[1][4] Plaintiffs in asbestos and talc cases have pointed to that combination — a statutory mandate, documented contamination, and the absence of a binding federal testing requirement — as part of the factual backdrop for claims that the cosmetics industry has not done enough to keep asbestos out of consumer talc.

For people diagnosed with Mesothelioma who have a history of cosmetic talc use, the relevant exposure question is whether the talc they used was contaminated with asbestos — the recognized carcinogen — not talc in the abstract. The federal framework described on this page, including the FDA's contamination findings and the surviving MoCRA mandate, is part of the documentary record that informs how those exposure histories are evaluated. (See also Asbestos Trust Funds and Talc Miners.)

Frequently Asked Questions

Is there a federal law requiring asbestos testing of talc in cosmetics?

There is a federal statute — the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) — that directs the FDA to establish standardized asbestos testing methods for talc-containing cosmetics. However, the specific rule that would have implemented mandatory testing was proposed in December 2024 and withdrawn on November 28, 2025, so as of 2026 there is no enforceable federal testing requirement in effect.[1][4]

When was the FDA talc testing rule withdrawn?

The FDA withdrew the proposed rule on November 28, 2025, under docket FDA-2023-N-4225. The original proposed rule had been published in the Federal Register on December 27, 2024 (89 FR 105490).[1][3]

Why did the FDA withdraw the rule?

The Federal Register withdrawal notice states the FDA acted in response to comments received during the comment period that warrant further consideration and assessment before final regulations are issued. The notice does not provide a timeline for a replacement rule.[1]

What did the FDA's 2019 testing find?

The FDA tested 52 talc-containing cosmetic products and found asbestos in 9 of them. The FDA cautions that this result should not be read as a marketplace contamination rate, because the sampled products were deliberately selected to include items previously flagged for possible contamination.[5][6]

Did the EPA ban asbestos in talc?

The EPA's March 2024 Risk Management Rule for Chrysotile Asbestos prohibits ongoing uses of chrysotile asbestos under TSCA, and the EPA separately assessed asbestos-containing talc as a potential exposure source. Cosmetics-specific testing, however, is the FDA's responsibility, not the EPA's.[7]

Is talc banned in the European Union?

Not yet, but it is on track to be. The EU's Risk Assessment Committee classified talc as a CMR Category 1B substance, and under Article 15 of the EU Cosmetics Regulation that classification is expected to lead to a ban on talc in cosmetics around 2027.[8]

Does the withdrawal mean cosmetic talc is now considered safe?

No. The withdrawal addressed a testing-method rule, not the underlying science. The IARC continues to classify talc as probably carcinogenic (Group 2A) and asbestos-containing talc as a Group 1 carcinogen, and the FDA's statutory obligation to set testing standards remains in force.[10][4]

Quick Statistics

  • 9 of 52 — talc-containing cosmetic products that tested positive for asbestos in the FDA's 2019 sampling assignment (enriched sample, not a marketplace rate).[6]
  • December 27, 2024 — date the FDA's proposed talc asbestos testing rule published (89 FR 105490).[3]
  • November 28, 2025 — date the FDA withdrew the proposed rule (docket FDA-2023-N-4225).[1]
  • 2 — analytical methods the proposed rule would have required (PLM and TEM/EDS/SAED).[3]
  • March 2024 — date the EPA finalized its Risk Management Rule for Chrysotile Asbestos.[7]
  • 6 — asbestos fiber types covered in the EPA's Part 2 legacy-use evaluation (chrysotile plus five amphiboles), in addition to Libby Amphibole Asbestos.[7]
  • Group 2A — IARC classification of talc; asbestos-containing talc remains in Group 1.[10]
  • ~2027 — expected effective window for the EU's talc cosmetics ban following CMR 1B classification.[8]

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products; Withdrawal, Food and Drug Administration, Federal Register, November 28, 2025 (Docket FDA-2023-N-4225).
  2. ↑ 2.0 2.1 2.2 2.3 2.4 Talc, U.S. Food and Drug Administration, Cosmetic Ingredients (status of testing rule and MoCRA mandate).
  3. ↑ 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 FDA Proposes Rule to Require Standardized Testing Methods for Detecting and Identifying Asbestos in Talc-Containing Cosmetic Products, U.S. Food and Drug Administration, December 2024.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 4.7 Modernization of Cosmetics Regulation Act of 2022 (MoCRA), U.S. Food and Drug Administration.
  5. ↑ 5.0 5.1 5.2 FDA Advises Consumers to Stop Using Certain Cosmetic Products, U.S. Food and Drug Administration (asbestos-positive products and recalls arising from the 2019 testing).
  6. ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 FDA Releases Data from the Agency's Year-Long Sampling Assignment to Test Talc-Containing Cosmetic Products for the Presence of Asbestos, U.S. Food and Drug Administration (marketplace-rate caveat).
  7. ↑ 7.00 7.01 7.02 7.03 7.04 7.05 7.06 7.07 7.08 7.09 EPA Actions to Protect the Public from Exposure to Asbestos, U.S. Environmental Protection Agency (Risk Management Rule for Chrysotile Asbestos, March 2024; asbestos-containing talc assessment; Part 2 legacy-use evaluation).
  8. ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 European Chemicals Agency (ECHA) Risk Assessment Committee classification of talc as a CMR Category 1B substance; under Article 15 of Regulation (EC) No 1223/2009 (EU Cosmetics Regulation), a cosmetics ban is expected around 2027.
  9. ↑ 9.0 9.1 IARC Monographs evaluate the carcinogenicity of talc and acrylonitrile, International Agency for Research on Cancer, Press Release No. 352, 2024.
  10. ↑ 10.0 10.1 10.2 10.3 10.4 IARC Monographs Volume 136: Talc and Acrylonitrile, International Agency for Research on Cancer, 2024 (talc classified Group 2A; asbestos-containing talc retained in Group 1).
  11. ↑ 11.0 11.1 FDA Releases Data from the Agency's 2023 Testing of Talc-Containing Cosmetic Products for Asbestos, U.S. Food and Drug Administration.
  12. ↑ Talc, U.S. Food and Drug Administration (talc and asbestos as co-occurring minerals).

Retrieved from "https://wikimesothelioma.com/w/index.php?title=FDA_and_EPA_Regulations_on_Talc_Asbestos_Testing&oldid=3600"